VHIO is taking part in the development of a latest-generation antibody that will offer an alternative for immunotherapy-resistant tumours
We are talking about GEN1046, one of [...]
VHIO’s Scientific Report 2021: Turning 15 and driving continued, ‘crystalized’ progress against cancer during COVID-19 pandemic waves
This year’s Scientific Report: Turning 15 and [...]
Precision medicine can help to improve existing therapies for patients with metastatic colorectal cancer
Colorectal cancer (CRC) accounts for approximately 10% [...]
Elena Garralda’s latest ESMO On target column: Age is ‘just a number’. Not so in clinical trial enrollment
In March this year, the U.S. Food [...]
VHIO is involved in the development of a new antibody targeting cancer stem cells of solid tumours
The new antibody, MCLA-158, targets both epidermal [...]
Precision medicine still has hurdles to overcome to reach all patients
Barcelona, 19 April 2022– Research has revolutionised [...]
RAD51 once again proves its precision as a biomarker for identifying and stratifying sub-type “HRD” tumours
The use of PARP inhibitors has proven [...]
The combination of immunotherapy plus pre-surgery chemotherapy improves event-free survival in patients with resectable non-small cell lung cancer
The results of the Phase III CheckMate-816 [...]
Triple therapy shows major benefits in the treatment of metastatic prostate cancer
A study performed by the European PEACE [...]
